Published in Prog Med Virol on January 01, 1982
Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67
Cell fusion by the envelope glycoproteins of persistent measles viruses which caused lethal human brain disease. J Virol (1993) 2.38
Multiple viral mutations rather than host factors cause defective measles virus gene expression in a subacute sclerosing panencephalitis cell line. J Virol (1988) 1.84
Transcription inhibition and other properties of matrix proteins expressed by M genes cloned from measles viruses and diseased human brain tissue. J Virol (1994) 1.42
Role of biased hypermutation in evolution of subacute sclerosing panencephalitis virus from progenitor acute measles virus. J Virol (1991) 1.41
Generalized and localized biased hypermutation affecting the matrix gene of a measles virus strain that causes subacute sclerosing panencephalitis. J Virol (1989) 1.28
Measles virus matrix protein detected by immune fluorescence with monoclonal antibodies in the brain of patients with subacute sclerosing panencephalitis. J Virol (1985) 1.15
The matrix proteins of neurovirulent subacute sclerosing panencephalitis virus and its acute measles virus progenitor are functionally different. Proc Natl Acad Sci U S A (1992) 1.07
Human cellular immune response to measles virus polypeptides. J Virol (1984) 1.07
Subacute sclerosing panencephalitis virus dominantly interferes with replication of wild-type measles virus in a mixed infection: implication for viral persistence. J Virol (1992) 1.03
Functional cDNA library for efficient expression of measles virus-specific gene products in primate cells. J Virol (1986) 0.98
Effect of papaverine treatment on replication of measles virus in human neural and nonneural cells. J Virol (1984) 0.97
Identification of interferon-resistant subpopulations in several strains of measles virus: positive selection by growth of the virus in brain tissue. J Virol (1990) 0.93
Irreversible modification of measles virus RNA in vitro by nuclear RNA-unwinding activity in human neuroblastoma cells. J Virol (1992) 0.89
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med (1993) 5.67
Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J Virol (1987) 5.45
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med (1994) 4.32
Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet (1993) 4.06
Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science (2000) 3.51
The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol (1994) 2.94
Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol (1990) 2.87
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis (1998) 2.24
Intracellular synthesis of measles virus-specified polypeptides. J Virol (1978) 2.21
The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript. J Virol (1996) 1.93
The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits. J Virol (2000) 1.57
Region of herpes simplex virus type 1 latency-associated transcript sufficient for wild-type spontaneous reactivation promotes cell survival in tissue culture. J Virol (2001) 1.55
An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation. J Virol (1995) 1.54
In vitro promoter activity associated with the latency-associated transcript gene of herpes simplex virus type 1. J Gen Virol (1989) 1.52
Immune response in subacute sclerosing panencephalitis: reduced antibody response to the matrix protein of measles virus. J Immunol (1979) 1.52
A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1. J Virol (1996) 1.51
Identification of a major regulatory sequence in the latency associated transcript (LAT) promoter of herpes simplex virus type 1 (HSV-1). Virology (1991) 1.48
Autoimmune hemolytic anemia in Kawasaki disease: a case report. Transfusion (1990) 1.47
Differences between the intracellular polypeptides of measles and subacute sclerosing panencephalitis virus. Nature (1978) 1.41
A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation. J Virol (1999) 1.35
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr (1998) 1.34
The region of the herpes simplex virus type 1 LAT gene that is colinear with the ICP34.5 gene is not involved in spontaneous reactivation. J Virol (1996) 1.25
Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J Virol (1994) 1.23
Purification of measles virus and characterization of subviral components. J Virol (1979) 1.20
Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr (1994) 1.17
The effect of latency-associated transcript on the herpes simplex virus type 1 latency-reactivation phenotype is mouse strain-dependent. J Gen Virol (2001) 1.17
The region of the herpes simplex virus type 1 LAT gene involved in spontaneous reactivation does not encode a functional protein. Virology (1998) 1.16
A simultaneous outbreak of respiratory syncytial virus and parainfluenza virus type 3 in a newborn nursery. J Pediatr (1984) 1.12
Molecular cloning and sequence analysis of the human parainfluenza 3 virus mRNA encoding the P and C proteins. Virology (1986) 1.12
Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring. Br J Ophthalmol (2000) 1.12
The role of natural killer cells in protection of mice against death and corneal scarring following ocular HSV-1 infection. Antiviral Res (2000) 1.11
Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins. Invest Ophthalmol Vis Sci (1995) 1.10
An improved method for cloning portions of the repeat regions of herpes simplex virus type 1. J Virol Methods (1994) 1.10
Three herpes simplex virus type 1 latency-associated transcript mutants with distinct and asymmetric effects on virulence in mice compared with rabbits. J Virol (2001) 1.09
Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D. Arch Virol (1991) 1.07
Cell surface expression of herpes simplex virus type 1 glycoprotein H in recombinant baculovirus-infected cells. Virology (1991) 1.07
Mapping herpes simplex virus type 1 latency-associated transcript sequences that protect from apoptosis mediated by a plasmid expressing caspase-8. J Neurovirol (2004) 1.06
Measles virus-specified polypeptide synthesis in two persistently infected HeLa cell lines. J Virol (1979) 1.06
Molecular cloning and sequence analysis of the human parainfluenza 3 virus RNA encoding the nucleocapsid protein. Virology (1986) 1.06
Visualization and mapping of late nuclear adenovirus RNA. Cell (1977) 1.02
Expression of the first 811 nucleotides of the herpes simplex virus type 1 latency-associated transcript (LAT) partially restores wild-type spontaneous reactivation to a LAT-null mutant. Virology (1999) 1.02
The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis (1999) 1.01
Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge. Virology (1992) 1.00
Immediate persistent infection by human parainfluenza virus 3: unique fusion properties of the persistently infected cells. J Gen Virol (1987) 1.00
A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest Ophthalmol Vis Sci (1998) 0.99
Expression of herpes simplex virus type 1 glycoprotein B in insect cells. Initial analysis of its biochemical and immunological properties. Virus Res (1992) 0.99
Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res (1995) 0.99
Intracellular synthesis of human parainfluenza type 3 virus-specified polypeptides. J Virol (1985) 0.98
The current status of chloramphenicol. Pediatrics (1979) 0.98
Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014;134(5):e1474-e1502. Pediatrics (2015) 0.97
Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr (1992) 0.96
M protein instability and lack of H protein processing associated with nonproductive persistent infection of HeLa cells by measles virus. Virology (1985) 0.95
Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice. J Virol (2001) 0.95
Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol (1998) 0.94
Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K. J Virol (1994) 0.93
The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge. Immunology (1998) 0.92
Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. J Virol (1999) 0.91
Baculovirus-expressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge. Virology (1992) 0.90
The US5 open reading frame of herpes simplex virus type 1 does encode a glycoprotein (gJ). Intervirology (1998) 0.90
Expression of herpes simplex virus type 1 glycoprotein I in baculovirus: preliminary biochemical characterization and protection studies. J Virol (1992) 0.90
The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Immunology (1997) 0.90
Either a CD4(+)or CD8(+)T cell function is sufficient for clearance of infectious virus from trigeminal ganglia and establishment of herpes simplex virus type 1 latency in mice. Microb Pathog (1999) 0.89
Anti-human cardiac myosin autoantibodies in Kawasaki syndrome. J Immunol (1999) 0.89
Cytokeratin provides a specific marker for human arachnoid cells grown in vitro. Exp Cell Res (1983) 0.89
Human parainfluenza virus 3: purification and characterization of subviral components, viral proteins and viral RNA. Virus Res (1985) 0.89
Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection. Antiviral Res (1992) 0.89
The UL3 open reading frame of herpes simplex virus type 1 codes for a phosphoprotein. Virus Res (1996) 0.89
MHC-II but not MHC-I responses are required for vaccine-induced protection against ocular challenge with HSV-1. Curr Eye Res (1997) 0.88
Meningococcal disease among children who live in a large metropolitan area, 1981-1996. Clin Infect Dis (2001) 0.88
Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations. Invest Ophthalmol Vis Sci (1997) 0.87
Molecular cloning and sequence analysis of the human parainfluenza 3 virus gene encoding the matrix protein. Virology (1987) 0.86
Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol (1994) 0.86
Possible association of intussusception with rotavirus vaccination. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics (1999) 0.86
Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection. Virology (1996) 0.85
A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation. Cancer Gene Ther (2001) 0.85
Neurocognitive abnormalities in children after classic manifestations of Lyme disease. Pediatr Infect Dis J (1998) 0.84
Prevention of nosocomial transmission of respiratory syncytial virus in a newborn nursery. Infect Control Hosp Epidemiol (1988) 0.84
A simple method for increased recovery of purified paramyxovirus virions. J Virol Methods (1985) 0.84
Specific and nonspecific immune stimulation of MHC-II-deficient mice results in chronic HSV-1 infection of the trigeminal ganglia following ocular challenge. Virology (1999) 0.84
Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr Infect Dis J (1995) 0.83
Sequence and comparative analysis of the genome of HSV-1 strain McKrae. Virology (2012) 0.83
Expression and characterization of baculovirus expressed herpes simplex virus type 1 glycoprotein L. Arch Virol (1994) 0.83
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. Pediatr Infect Dis J (2000) 0.83
Antibody-dependent enhancement of HSV-1 infection by anti-gK sera. Virus Res (2000) 0.82
Perforin pathway is essential for protection of mice against lethal ocular HSV-1 challenge but not corneal scarring. Virus Res (1999) 0.82
Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest Ophthalmol Vis Sci (1990) 0.81
The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum (1998) 0.81
Ribavirin administration to infants receiving mechanical ventilation. Am J Dis Child (1988) 0.81
Vaccination with different HSV-1 glycoproteins induces different patterns of ocular cytokine responses following HSV-1 challenge of vaccinated mice. Vaccine (1999) 0.81
The persistent elevated cytokine mRNA levels in trigeminal ganglia of mice latently infected with HSV-1 are not due to the presence of latency associated transcript (LAT) RNAs. Virus Res (1998) 0.79
Similarities in regulation of the HSV-1 LAT promoter in corneal and neuronal cells. Invest Ophthalmol Vis Sci (1994) 0.79
Superantigens in Kawasaki syndrome. Clin Immunol Immunopathol (1995) 0.78
Respiratory syncytial virus immunoprophylaxis: impact on epidemiology. Paediatr Drugs (2000) 0.77